Sign up to save your podcasts
Or
Share The Power of Triglyceride Research
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
The Power of Triglyceride Research
In this week's episode, we explore hypertriglyceridemia: high triglyceride levels in the blood. We look at what triglycerides are, why they might be elevated, and some of the risks and causes of hypertriglyceridemia. We also look at the pivotal role clinical research has and continues to play in controlling this dangerous condition, and give a powerful look at what's being investigated now in the research space.
References:
- Reeskamp LF, Tromp TR, Stroes ES. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?. Current opinion in lipidology. 2020 Jun 1;31(3):140-6. https://doi.org/10.1097/MOL.0000000000000679
- Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. European heart journal. 2020 Jan 1;41(1):99-109c. https://doi.org/10.1093/eurheartj/ehz785
- Mohamed F, Mansfield BS, Raal FJ. ANGPTL3 as a drug target in hyperlipidemia and atherosclerosis. Current Atherosclerosis Reports. 2022 Dec;24(12):959-67. https://doi.org/10.1007/s11883-022-01071-1
- Ward NC, Chan DC, Watts GF. A tale of two new targets for hypertriglyceridaemia: which choice of therapy?. BioDrugs. 2022 Mar 14;36(2):121. https://doi.org/10.1007/s40259-022-00520-2
- Robciuc MR, Maranghi M, Lahikainen A, Rader D, Bensadoun A, Öörni K, Metso J, Minicocci I, Ciociola E, Ceci F, Montali A. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arteriosclerosis, thrombosis, and vascular biology. 2013 Jul;33(7):1706-13. https://doi.org/10.1161/ATVBAHA.113.301397
- Reeskamp, L. F., Tromp, T. R., Huijgen, R., Stroes, E. S., Hovingh, G. K., & Grefhorst, A. (2020). Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation. Atherosclerosis, 315, 68-75. https://doi.org/10.1016/j.atherosclerosis.2020.11.013
Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
Twitter
LinkedIn
Tiktok
Youtube
For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! Podcast and MedEvidence.com
Thank you for listening!
View all episodes
By MedEvidence ArticlesIn this week's episode, we explore hypertriglyceridemia: high triglyceride levels in the blood. We look at what triglycerides are, why they might be elevated, and some of the risks and causes of hypertriglyceridemia. We also look at the pivotal role clinical research has and continues to play in controlling this dangerous condition, and give a powerful look at what's being investigated now in the research space.
References:
- Reeskamp LF, Tromp TR, Stroes ES. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?. Current opinion in lipidology. 2020 Jun 1;31(3):140-6. https://doi.org/10.1097/MOL.0000000000000679
- Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. European heart journal. 2020 Jan 1;41(1):99-109c. https://doi.org/10.1093/eurheartj/ehz785
- Mohamed F, Mansfield BS, Raal FJ. ANGPTL3 as a drug target in hyperlipidemia and atherosclerosis. Current Atherosclerosis Reports. 2022 Dec;24(12):959-67. https://doi.org/10.1007/s11883-022-01071-1
- Ward NC, Chan DC, Watts GF. A tale of two new targets for hypertriglyceridaemia: which choice of therapy?. BioDrugs. 2022 Mar 14;36(2):121. https://doi.org/10.1007/s40259-022-00520-2
- Robciuc MR, Maranghi M, Lahikainen A, Rader D, Bensadoun A, Öörni K, Metso J, Minicocci I, Ciociola E, Ceci F, Montali A. Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Arteriosclerosis, thrombosis, and vascular biology. 2013 Jul;33(7):1706-13. https://doi.org/10.1161/ATVBAHA.113.301397
- Reeskamp, L. F., Tromp, T. R., Huijgen, R., Stroes, E. S., Hovingh, G. K., & Grefhorst, A. (2020). Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation. Atherosclerosis, 315, 68-75. https://doi.org/10.1016/j.atherosclerosis.2020.11.013
Share with a friend. Rate, Review, and Subscribe to MedEvidence! Articles to be notified when new episodes are released.
Follow us on Social Media:
Facebook
Instagram
Twitter
LinkedIn
Tiktok
Youtube
For more great content, including discussions by physicians and clinical research experts, check out the MedEvidence! Podcast and MedEvidence.com
Thank you for listening!